B16-F1 Syngeneic Model Overview

The B16-F1 syngeneic model is a murine melanoma system derived from a spontaneous melanoma in C57BL/6 mice and represents the low-metastatic variant of the B16 melanoma family. As an early clonal derivative of the parental B16 line, B16-F1 demonstrates controlled local tumor growth with limited spontaneous dissemination, providing a valuable contrast to the highly metastatic B16-F10 model. This model is frequently used for preclinical studies investigating primary tumor immunity, early tumor–immune interactions, and the efficacy of immunotherapies in a less aggressive but immunologically relevant melanoma system.

When implanted subcutaneously or intradermally into C57BL/6 mice, B16-F1 tumors develop consistently and display the characteristic pigmentation typical of melanoma due to melanin accumulation. The model’s slower growth rate and reduced metastatic potential make it particularly well suited for longitudinal studies of immune infiltration, checkpoint blockade, and combination immunotherapy aimed at transforming “cold” melanoma into an immune-responsive phenotype.

Request a Custom Quote for B16F1 Syngeneic Model

Biological and Molecular Characteristics

The B16-F1 cell line was established as one of the first subclones derived from the parental B16 melanoma. Compared with B16-F10, the F1 variant exhibits lower metastatic capability, milder invasive behavior, and a more stable growth profile. Tumor cells display spindle-like morphology, moderate pigmentation, and high mitotic activity. Molecularly, B16-F1 expresses melanoma-associated antigens such as gp100, TRP-2, and tyrosinase, which are frequently targeted in immunotherapy development.

Despite its relatively low intrinsic immunogenicity, B16-F1 tumors can elicit modest immune responses and are commonly used to evaluate immunomodulatory treatments that enhance antigen presentation or overcome myeloid-derived suppression. The tumor microenvironment is characterized by limited CD8⁺ T-cell infiltration and abundant macrophages and fibroblasts, mimicking the immune exclusion seen in many human melanomas.

Parameter	Description
Host strain	C57BL/6 (female, 6–8 weeks)
Tumor origin	Spontaneous melanoma (mouse)
Histological type	Poorly differentiated melanoma
Inoculation route	Subcutaneous, intradermal, or intravenous
Tumor take rate	>90%
Doubling time	Approximately 3–4 days in vivo
Metastatic potential	Low; limited spontaneous dissemination
Immunophenotype	Weakly immunogenic; macrophage-dominant stroma
Common applications	Immunotherapy, checkpoint blockade, vaccine development

In Vivo Model Development and Tumorigenicity

The B16-F1 model is typically established by subcutaneous implantation of tumor cells into immunocompetent C57BL/6 mice. Palpable tumors appear within 6–8 days post-inoculation, showing gradual expansion and reproducible kinetics. The model demonstrates minimal spontaneous metastasis under standard conditions, but experimental lung metastases can be generated following intravenous injection for comparative analyses against B16-F10.

Due to its moderate tumor progression rate, B16-F1 is suitable for extended observation and repeated immune monitoring. This feature allows comprehensive evaluation of immune cell infiltration, cytokine secretion, and tumor regression dynamics in response to immunotherapy. The model’s slower kinetics also facilitate mechanistic studies of antigen presentation, immune escape, and macrophage polarization without the confounding effects of rapid metastatic spread.

Request a Custom Quote for B16F1 Syngeneic Model

Histopathology and Immunohistochemical Profile

Histological evaluation of B16-F1 tumors reveals spindle-shaped, melanin-producing cells arranged in interlacing bundles within a poorly vascularized stroma. The tumors exhibit moderate cellular density, with focal areas of necrosis and infiltration by inflammatory cells. Compared to the B16-F10 variant, B16-F1 tumors are more compact and less invasive, displaying reduced vascular density and stromal desmoplasia.

Immunohistochemical analyses show Ki-67 positivity consistent with active but controlled proliferation. CD3 and CD8 staining reveal sparse T-cell infiltration, while F4/80 and CD11b staining indicate abundant macrophage and myeloid cell presence throughout the tumor periphery. PD-L1 expression is typically low at baseline but increases under interferon stimulation or immunotherapeutic pressure. The histological and immunophenotypic characteristics of B16-F1 tumors provide an effective framework for studying immune exclusion, stromal remodeling, and early immune recognition in melanoma.

Preclinical Applications and Drug Response

The B16-F1 syngeneic model is widely used in preclinical research focused on immunotherapy development, melanoma immunobiology, and combination therapeutic strategies. Its controlled tumor growth and low metastatic potential make it ideal for mechanistic investigations into T-cell recruitment, immune priming, and checkpoint inhibitor responsiveness. The model exhibits limited intrinsic sensitivity to PD-1 or CTLA-4 blockade, reflecting its immune-cold phenotype, but shows enhanced responses when combined with cytokine agonists, oncolytic viruses, or therapeutic vaccines targeting melanoma-associated antigens.

Studies using the B16-F1 model have demonstrated that interventions increasing antigen presentation or reducing stromal immunosuppression significantly enhance T-cell infiltration and improve therapeutic efficacy. As a result, B16-F1 serves as a valuable complement to the more aggressive B16-F10 model, allowing side-by-side comparison of therapeutic effects across the metastatic spectrum of murine melanoma. Its reproducibility and immunological tractability make it an indispensable component of melanoma-focused preclinical research.

Request This Model

To request the B16-F1 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for B16F1 Syngeneic Model